Caroline Seymour joined MJH Life Sciences in 2018 and has expertise in video production and print/digital publication. Email: cseymour@onclive.com
N-803 BLA Undergoes Review For BCG-Unresponsive Non–Muscle Invasive Bladder Cancer in Situ
August 10th 2022A biologics license application for the IL-15 superagonist N-803 has been accepted and the agent will be reviewed for the treatment of patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer carcinoma in situ.
Mosunetuzumab Receives Priority Review Designation for Relapsed/Refractory Follicular Lymphoma
July 22nd 2022Mosunetuzumab, a CD20 and CD3 T-cell engaging bispecific antibody, received a priority review designation from the FDA for the treatment of patients with relapsed/refractory follicular lymphoma following at least 2 prior systemic therapies.
Mirvetuximab Soravtansine Is Under Priority Review for FRα-High, Platinum-Resistant Ovarian Cancer
July 18th 2022Mirvetuximab soravtansine (IMGN853) has been granted priority review by the FDA for the treatment of patients with FRα-high, platinum-resistant ovarian cancer who have previously received between 1 and 3 systemic therapies.
Superior Pathologic Complete Responses in NSCLC Tied to Durvalumab/Chemotherapy Combo
July 16th 2022Phase 3 findings from the AEGEAN trial demonstrated that adding durvalumab to platinum-based chemotherapy regimens improved pathologic complete response and major pathologic response among patients with resectable non–small cell lung cancer.
RVd Plus ACST and Lenalidomide Maintenance Promote Efficacy in Newly Diagnosed Multiple Myeloma
June 8th 2022Patients with multiple myeloma who received initial combination therapy with lenalidomide, bortezomib, and dexamethasone, plus autologous stem cell transplant, followed by lenalidomide maintenance, experienced improved progression-free survival.
NCCN Clinical Practice Guidelines Now Include Duvelisib for Peripheral T-cell Lymphoma
March 17th 2022Duvelisib, a dual PI3K-δ,γ inhibitor, is now listed as a category 2A designated option for second-line and subsequent treatment of patients with relapsed/refractory peripheral T-cell lymphoma in the National Comprehensive Cancer Network Clinical Practice Guidelines.
CPX-351 Continues to Improve Survival in Older Patients With AML
July 12th 2021Data from a 5-year follow-up study confirmed that CPX-351 continues to be associated with long-term remission and improved overall survival compared to 7+3 chemotherapy in certain older patients with acute myeloid leukemia.